10-K: Forian Inc. Reports Restated 2024 Annual Results, Cites Material Weaknesses in Internal Controls

Forian Inc.'s 10-K filing reveals restated financial statements for 2023 due to revenue recognition errors and identifies material weaknesses in internal controls over financial reporting.

Summary

• Forian Inc. has filed its annual report on Form 10-K, including restated consolidated financial statements for 2023 and identification of material weaknesses in internal control over financial reporting.
• The restatement was due to an error in revenue recognition under ASC 606, where aggregate annual minimum payments for certain contracts should have been recognized on a straight-line basis.
• The restatement increased previously reported revenues by $1.7 million and net income by $1.5 million on a cumulative basis since the company's inception as a public company in 2021.
• The company identified material weaknesses in internal control related to the validation of payables transactions and the application of ASC 606 for revenue recognition.
• Revenues for 2024 decreased to $20.15 million from $21.22 million in 2023, primarily due to customer contract expirations and attrition.
• The company completed the acquisition of Kyber Data Science LLC on October 31, 2024, which contributed to the company's revenues.
• The company had cash and marketable securities totaling $35.08 million as of December 31, 2024, with $6.70 million outstanding in convertible notes due September 1, 2025.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the acquisition of Kyber is a positive development, the restatement of financial statements, identification of material weaknesses, and decrease in revenue indicate challenges. The sentiment is cautiously negative.

Positives

• The company completed the acquisition of Kyber Data Science LLC, expanding its offerings.
• The company is implementing enhanced controls to address the identified material weaknesses.
• The company has a significant amount of cash and marketable securities on hand.
• The company settled outstanding claims filed against the company and certain of its subsidiaries.

Negatives

• The company restated its 2023 financial statements due to revenue recognition errors.
• Material weaknesses were identified in internal controls over payables and revenue recognition.
• Revenues decreased in 2024 compared to 2023.
• The company experienced reductions in data licensed from certain of its data suppliers as a result of restrictions imposed by its suppliers upstream data licensors.

Risks

• The company has a limited operating and financial history.
• The company may need additional capital to fund its operations.
• The company could lose access to data from external sources.
• The company may not be able to successfully manage its intellectual property and may be subject to infringement claims.
• Security breaches and unauthorized use of the company's systems and information could expose the company, its customers, its data suppliers or others to risk of loss.
• Federal and state privacy and data protection laws are evolving and compliance with applicable requirements may increase the company's operating costs or adversely impact its ability to service its customers and market its products and services.

Future Outlook

The company expects to continue to fund its operations and potential future acquisitions through a combination of cash flow generated from operating activities, available cash and marketable securities, debt financing and/or additional equity issuances.

Industry Context

The company operates in the data science-driven information and analytics solutions market, serving the life science, healthcare, and financial services industries, which are experiencing increasing demand for data-driven insights to optimize performance.

Comparison to Industry Standards

• The document mentions competitors such as ICON plc, IQVIA, Veeva Systems, Inc., and Definitive Healthcare Corp.
• These companies are well-capitalized and experienced in the healthcare and information analytics industries.
• Forian believes its unique data assets, synergies, intellectual property, and experienced leadership offer competitive advantages.

Management Changes

Legal Proceedings

• The company settled the Audet v. Green Tree International, et. al. lawsuit.
• The company settled the Grant Whitus et al. v. Forian Inc., Zachary Venegas and Scott Ogur lawsuit.

Related Party Transactions

• Adam Dublin, the company's Chief Strategy Officer, received payments from a current vendor of the company for runoff commissions.
• The company issued convertible promissory notes to a select group of investors, which included a director of the company.
• The company repurchased shares of its common stock from a group of affiliated investors in a privately negotiated transaction.
• The company entered a customer agreement with an entity controlled by one of its directors providing for products and services over a three year period for variable consideration with aggregate minimum billings of $1,200,000.

Stakeholder Impact

• Shareholders may be concerned about the restatement of financial statements and the identified material weaknesses.
• Employees may be affected by the company's efforts to remediate the material weaknesses.
• Customers may be impacted by the company's efforts to transition to replacement data sources.
• Suppliers may be affected by the company's efforts to license data from additional vendors.

Next Steps

• The company intends to remediate the identified material weaknesses in internal control over financial reporting.
• The company will continue to invest in commercial sales, research and development, and strategic partnerships.
• The company will continue to evaluate any impact on customer performance commitments and the availability of alternate sources of comparable data.

Key Dates

Keywords

financial statements, internal control, revenue recognition, material weakness, acquisition, Kyber, Forian, restatement